Germany’s BioNTech (Nasdaq: BNTX), which shot into the limelight with the development of the first and most successful COVID-19 vaccine, Comirnaty, partnered with Pfizer (NYSE: PFE), today reported financial results for the three months ended June 30, 2023.
BioNTech shares were down more than 6% at $99.82 in pre-market activity following the announcement.
Total revenues reported were 167.7 million euros ($184.8 million) for the second quarter, well short of FactSet consensus of 628.1 million euros, and compared to 3,196.5 million euros for the comparative prior year period, as well as a swinging to a net loss of 190.4 million euros that beat forecasts. The earnings per share (EPS) loss was 0.79 euros, versus, 6.45 euros profit a share the year earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze